Skip to main content
Home
    • en
    • fr
  • Search form

Main menu

  • About us
    • Our mission
    • Facts & Figures
    • Our Strategy
    • Corporate Governance/ Executive Committee
    • bioMérieux Worldwide
    • Our History
    • Innovation
    • Institut Mérieux

  • Responsibility
    • Our ambition
    • Health
    • Planet
    • Healthcare ecosystem
    • Employees
    • Extended Company
    • SantéRESISTANCE TO ANTIBIOTICS
    • PlanèteCOVID-19 EXCEPTIONAL DONATIONS
  • Solutions
    • Clinical Solutions
    • Industry Solutions
    • Product Quality & Safety
    • Customer Service
    • Cybersecurity
    • Technical Library
    • CLINICAL SOLUTIONS
    • INDUSTRY SOLUTIONS
  • Expertise
    • The importance of diagnostics
      • Clinical diagnostics
      • Industrial Microbiological Control
    • Clinical applications
      • Infectious diseases
      • COVID-19
      • Antimicrobial resistance and Healthcare-associated infections
      • Cardiovascular Emergencies
      • Personalized medicine
    • Industrial applications
      • Agri-food sector
      • Biopharma & cosmetics sectors
    • Our technologies, systems and services
      • Microbiology
      • Molecular Biology
      • Immunoassays
      • Services
    • Glossary of Scientific Terms
  • Education
    • Antimicrobial Resistance / Antimicrobial Stewardship
      • Webinars
      • Educational Materials
      • External Resources
    • Sepsis / Bloodstream Infections
      • Webinars
      • Educational Tutorials
      • Educational Materials
      • External Resources
    • COVID-19
      • Webinars
    • Acute Kidney Injury
      • Webinars & Symposiums
      • Educational Materials
      • External Resources
    • Educational booklets
  • Investors
    • The bioMérieux Share
    • Publications
    • Regulated Information
    • Governance
    • Shareholder area
    • UNIVERSAL REGISTRATION DOCUMENT
    • CORPORATE SOCIAL RESPONSIBILITY
  • Newsroom
    • Press Releases
    • Corporate calendar
    • Media Center
    • About bioMérieux
    • bioMérieux announces the CE marking of 3 dengue immunoessays on VIDAS®
    • PRESS CONTACTS
     
  • Careers
    • Joining bioMérieux
      • Corporate culture
      • Public health mission
      • International presence
      • Professional development
      • Diversity and inclusion
      • Well-being at work
      • Compensation and benefits
    • Job Profiles
      • R&D
      • Manufacturing
      • Supply Chain
      • Information Systems
      • Quality
      • Business
      • Support Functions
      • Medical Affairs
      • HSE
      • Clinical Affairs and Regulatory Affairs
  • Contact us
Home
  • About us
    • Our mission
    • Facts & Figures
    • Our Strategy
    • Corporate Governance/ Executive Committee
    • bioMérieux Worldwide
    • Our History
    • Innovation
    • Institut Mérieux
  • Responsibility
    • Our ambition
    • Health
    • Planet
    • Healthcare ecosystem
    • Employees
    • Extended Company
  • Solutions
    • Clinical Solutions
    • Industry Solutions
    • Product Quality & Safety
    • Customer Service
    • Cybersecurity
    • Technical Library
  • Expertise
    • The importance of diagnostics
    • Clinical applications
    • Industrial applications
    • Our technologies, systems and services
    • Glossary of Scientific Terms
  • Education
    • Antimicrobial Resistance / Antimicrobial Stewardship
    • Sepsis / Bloodstream Infections
    • COVID-19
    • Acute Kidney Injury
    • Educational booklets
  • Investors
    • The bioMérieux Share
    • Publications
    • Regulated Information
    • Governance
    • Shareholder area
  • Newsroom
    • Press Releases
    • Corporate calendar
    • Media Center
    • About bioMérieux
  • Careers
    • Joining bioMérieux
    • Job Profiles
  • Contact us
    • Investor Relations
    • Press Contacts
    • en
    • fr
  • Search form

You are here

Printer-friendly version
  • Home
  • Universal Registration Document 2020 including Annual Financial Report (iXBRL)

Universal Registration Document 2020 including Annual Financial Report (iXBRL)

April 07, 2021
Download
Pioneering diagnostics
  • Legal Notice
  • Privacy
  • Cookie Policy
  • Contact
  • Copyright 2020 bioMérieux SA
  • biomerieux.com
  • bioMérieux Worldwide >
    Discover all our locations
    Asia
    • China (Website)
    • India (Website)
    • Indonesia (website)
    • Japan (Website)
    • Korea
    • Malaysia (website)
    • Philippines (website)
    • Singapore (Website)
    • Thailand (website)
    • Vietnam (website)
    Europe, Middle East, Africa
    • Algeria
    • Austria (Website)
    • Belgium
    • Czech Republic (Website)
    • Denmark (Website)
    • Finland (Website)
    • France (Website)
    • Germany (Website)
    • Greece
    • Hungary (Website)
    • Italy (Website)
    • Ivory Coast
    • Netherlands
    • Norway (Website)
    • Poland (Website)
    • Portugal (Website)
    • Russia (Website)
    • Serbia
    • South Africa (Website)
    • Spain (Website)
    • Sweden (Website)
    • Switzerland (Website)
    • Turkey (Website)
    • United Arab Emirates
    • United Kingdom (Website)
    North America
    • Canada (Website)
    • United States (Website)
    Oceania
    • Australia (Website)
    • New Zealand (Website)
    South America
    • Argentina (Website)
    • Brazil (Website)
    • Chile (Website)
    • Colombia (Website)
    • Mexico (Website)
  • Our Specific Websites >
    • Antimicrobial Resistance Website
    • BioFire Diagnostics
    • bioMérieux Clinical Diagnostics
    • bioMérieux Industry
    • bioMérieux Investors
    • bioMérieux Recruitment
    • bioMérieux Culture Media
  • Our communities >
    • mybiomerieux.com